Amarin Corporation plc (AMRN)
- Previous Close
10.52 - Open
10.58 - Bid 10.40 x 100
- Ask 10.70 x 100
- Day's Range
10.34 - 10.70 - 52 Week Range
7.00 - 18.00 - Volume
59,937 - Avg. Volume
97,313 - Market Cap (intraday)
219.08M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-4.40 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
www.amarincorp.com275
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AMRN
View More
Performance Overview: AMRN
Trailing total returns as of 5/17/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMRN
View MoreValuation Measures
Market Cap
219.08M
Enterprise Value
-54.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.02
Price/Book (mrq)
0.46
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.07%
Return on Assets (ttm)
-5.06%
Return on Equity (ttm)
-17.25%
Revenue (ttm)
214.11M
Net Income Avi to Common (ttm)
-87.93M
Diluted EPS (ttm)
-4.40
Balance Sheet and Cash Flow
Total Cash (mrq)
281.79M
Total Debt/Equity (mrq)
2.18%
Levered Free Cash Flow (ttm)
9.06M